Oxford Immunotec Reports Third Quarter 2018 Financial Results

Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT®.TB tests sold in the third quarter exceeded one million tests for the first time Significant improvement in GAAP net loss; first quarter of positive non-GAAP adjusted EBITDA OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced third quarter 2018 financial results.  “We are very pleased with the continued strong growth in our TB business, as well as the Company’s continued progress on profitability metrics,” said Dr. Peter Wrighton-Smith, Chief Executive Officer ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 7

Ähnlich Nachrichten